Ara-290 information is provided for general educational and research reference only. This section presents general scientific background and research-related information.
Educational overview for research reference and general information.
| Phase | Daily Blend (mg) | Volume (mL) |
|---|---|---|
| Week 1 | 2 mg (2,000 mcg) | 25 units (0.25 mL) |
| Weeks 2–8 (or up to 16) | 4 mg (4,000 mcg) | 50 units (0.50 mL) |
Research Information Steps
Plan based on general research information and educational reference materials.
Concise summary of general research information based on available scientific references.
General overview of research-related information and scientific references.
General handling information is provided for research reference.
Practical considerations for consistency and research reference.
Observations from preclinical and research literature.
Complementary strategies for general wellness and consistency.
General research handling information from educational reference resources.
Explore related research information and background reading for Ara-290.
— Dahan A. et al.: ARA 290 improves symptoms in Research Information Guide-associated small nerve fiber loss and increases corneal nerve fiber density
— Phase 2 study of ARA 290 on corneal nerve fiber density in Research Information Guide (1 mg vs 4 mg vs 8 mg daily SC for 28 days)
— Cibinetide improves corneal nerve fiber abundance in patients with Research Information Guide-associated small fiber neuropathy
— General Research Information and Scientific Background
Explore related research information and background reading.